Home/ Peptides/ MOTS-c

Back to all peptides

MOTS-c

MOTS-c is a small peptide made inside your own mitochondria. Your body produces less of it as you age, and exercise is the most reliable way to increase it naturally. Researchers have studied it for metabolic health, insulin sensitivity, and age-related decline. We read the evidence plainly, set expectations honestly, and only consider it for patients whose full clinical picture makes sense.

Compliance Notice: Important status notice. MOTS-c is not FDA approved for any therapeutic use. It is on the FDA Category 2 restricted list, which means licensed compounding pharmacies cannot prepare it. Any use at Paragon is research-informed, under direct physician supervision, and only after a full clinical review. The only completed human trial used a modified version of MOTS-c developed by a company that has since discontinued operations. No Phase 1 safety trial has been completed for native MOTS-c.

WADA prohibition. MOTS-c was added to the WADA Prohibited List on January 1, 2024 under the S0 category (Non-Approved Substances) and appears on the 2025 list as an example under S4 (Hormone and Metabolic Modulators). It is prohibited at all times, in and out of competition, in every WADA-regulated sport. If you compete at any level in a WADA-regulated sport, MOTS-c is not appropriate for you. Do not use it.

Book a Consultation

Overview

MOTS-c is a peptide your mitochondria produce and release into circulation. It acts as a signaling molecule, telling the rest of your body (especially skeletal muscle) to take up glucose more efficiently and use energy better. It is one of the ways your mitochondria communicate with the rest of you, and it is part of why exercise improves metabolic health.

Two things about MOTS-c are unusually well characterized for a peptide this young in the literature. First, your blood levels of it decline with age, and patients with obesity and metabolic disease have lower levels than healthy controls. Second, exercise acutely raises both muscle and circulating MOTS-c, with skeletal muscle levels increasing nearly twelvefold during and after exertion. That is a clear biological story. As you get older and more sedentary, your own MOTS-c drops, and that drop tracks with metabolic decline.

The therapeutic idea is to supplement the peptide in patients whose endogenous signaling has fallen off. The idea is compelling. The human outcome data to support it is limited, and we say so up front.

CHEMICAL STRUCTURE & PROPERTIES

  • Origin: Mitochondrial-derived peptide; encoded in the mitochondrial 12S rRNA
  • Amino Acid Length: 16 residues
  • Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
  • Primary Target: AMPK (AMP-activated protein kinase)
  • Natural Trigger: Exercise; declines with age and metabolic disease
  • Route: Subcutaneous injection
  • Stability: Lyophilised powder; store at 2 degrees C to 8 degrees C before reconstitution
  • WADA Status: Prohibited -- S0 and S4 (2024 onward); not for competitive athletes

Mechanism of Action

MOTS-c exerts its metabolic effects through multiple interconnected mechanisms centered on mitochondrial signaling and glucose handling:

AMPK Activation

MOTS-c's primary mechanism runs through the same pathway as metformin, one of the most studied metabolic drugs in medicine:
  • MOTS-c activates AMPK (AMP-activated protein kinase), a master regulator of cellular energy balance
  • AMPK activation improves glucose uptake in skeletal muscle independent of insulin
  • This is the same pathway metformin activates, giving MOTS-c a well-characterized mechanistic anchor
  • AMPK activation also promotes fat oxidation and inhibits fat storage pathways

Skeletal Muscle Glucose Handling

Skeletal muscle is the primary site of MOTS-c action and the tissue most relevant to insulin resistance:
  • Exercise raises skeletal muscle MOTS-c levels nearly twelvefold during and after exertion
  • MOTS-c improves insulin sensitivity in skeletal muscle in animal models
  • It enhances glucose transporter activity, supporting non-insulin-dependent glucose uptake
  • Age-related decline in MOTS-c tracks directly with the loss of muscle metabolic flexibility

Mitochondrial Signaling and Energy Metabolism

MOTS-c acts as a communication signal from the mitochondria to the rest of the body:
  • It is produced inside mitochondria and released into circulation, making it a true mitochondrial hormone
  • Blood levels reflect the health and activity of your mitochondrial network
  • MOTS-c coordinates cellular responses to metabolic stress, including improved fat utilization
  • In animal models, MOTS-c preserves mitochondrial function and reduces age-related metabolic deterioration

Age-Related Metabolic Decline

The relationship between MOTS-c, aging, and metabolic disease is one of the best-characterized aspects of this peptide:
  • Circulating MOTS-c declines with age in humans and correlates with metabolic health markers
  • Patients with obesity and metabolic disease have lower MOTS-c levels than healthy controls
  • In aged animal models, MOTS-c administration restores metabolic profiles toward younger patterns
  • In high-fat-diet mouse models, MOTS-c prevented obesity and preserved metabolic flexibility

Clinical Applications and

Research Evidence

Insulin Resistance and Metabolic Health

Primary Investigation: Observational studies in humans confirm that circulating MOTS-c levels correlate with metabolic health markers and decline with age and metabolic disease.

  • Circulating MOTS-c levels are lower in patients with obesity, metabolic syndrome, and type 2 diabetes
  • In animal models, MOTS-c improves insulin sensitivity and glucose handling in skeletal muscle
  • AMPK activation by MOTS-c mirrors the mechanism of metformin, giving the pathway strong mechanistic credibility
  • The one human trial (CB4211, a modified analogue) met its Phase 1 safety endpoint and showed modest improvements in liver enzymes and glucose

Mechanism: MOTS-c activates AMPK in skeletal muscle, improving glucose uptake and insulin sensitivity through a pathway that does not require insulin itself -- directly addressing the muscle-level dysfunction driving insulin resistance.

Age-Related Metabolic Decline and Longevity

Emerging Applications: MOTS-c's role in aging and mitochondrial health has been studied in animals and observational human data over more than a decade.

  • MOTS-c levels decline with age in humans, tracking the loss of metabolic flexibility and muscle quality
  • In aged animal models, systemic MOTS-c restores metabolic profiles toward younger patterns
  • Cardiac function preservation has been demonstrated in animal models of aging
  • Exercise-related adaptations are enhanced by MOTS-c in preclinical models, suggesting a role in supporting training response

Mechanism: As a mitochondrial-derived signal that declines with age, MOTS-c supplementation attempts to restore the signaling environment that supports metabolic health -- addressing the drop in endogenous production that tracks with aging and sedentary behavior.

Metabolic Flexibility and Body Composition

Research Potential: Preclinical data on fat metabolism and body composition provides the basis for considering MOTS-c in patients with metabolic dysfunction, with appropriate expectations.

  • In high-fat-diet mouse models, MOTS-c prevented obesity without reducing food intake
  • MOTS-c promotes fat oxidation and inhibits fat storage pathways through AMPK
  • Lean body mass preservation has been observed in animal models alongside metabolic improvements
  • Human body composition effects have not been established; we do not prescribe MOTS-c as a weight-loss peptide

Mechanism: AMPK activation shifts cellular metabolism toward fat utilization and away from fat storage, with downstream effects on body composition in animal models -- a finding that has not yet been replicated in human trials.

Current Clinical Evidence

Published Human Studies

The human data on MOTS-c is limited to observational studies and one Phase 1 trial of a modified analogue.

  • Observational studies confirm MOTS-c levels correlate with metabolic health and decline with age in humans
  • One Phase 1a/1b trial (CB4211, a modified MOTS-c analogue) enrolled 85 participants (healthy volunteers and NAFLD patients)
  • CB4211 met its primary safety endpoint; modest improvements in liver enzymes and glucose were observed
  • CB4211 did not complete Phase 2; the developing company (CohBar) has since discontinued operations

What the Research Has Not Yet Settled

The preclinical story is strong. The human clinical story is thin.

  • No completed Phase 1 safety or pharmacokinetic trial exists for native MOTS-c
  • The only human trial used a modified analogue developed by a company that no longer operates
  • Formal genotoxicity, carcinogenicity, and reproductive toxicity studies have not been conducted
  • Drug interaction data with insulin, GLP-1 agonists, and other glucose-lowering agents has not been formally studied

Research Limitations

Current evidence is constrained by:

  • Absence of a completed Phase 1 trial for native MOTS-c
  • Human efficacy data limited to a single Phase 1 trial of a modified analogue that did not reach Phase 2
  • All metabolic efficacy findings come from animal models and observational human studies
  • WADA prohibition limits athlete-population research and creates additional access constraints
  • FDA Category 2 classification reflects the regulatory assessment of this evidence gap

Safety Considerations

Clinical Safety Data

The modified MOTS-c analogue CB4211 met its Phase 1 safety endpoint in a trial of 85 participants. Those are the best available human safety data.

  • No serious adverse events were reported in the CB4211 Phase 1 trial
  • The most common adverse event was injection site reaction related to the modified peptide's retention at the injection site
  • No hepatotoxicity or nephrotoxicity signal has appeared in preclinical studies of native MOTS-c
  • No cancer safety data exists; we do not use MOTS-c in patients with active or previously treated malignancy

Monitoring and Response

We screen carefully before prescribing and monitor closely throughout.

  • Fasting insulin, HbA1c, glucose handling, body composition, relevant lipid markers, and subjective report are tracked
  • Labs are re-checked on a schedule that matches your protocol
  • For patients on insulin or other glucose-lowering medications, coordination is required before prescribing given the potential for additive glucose-lowering effects
  • If your response during the protocol is not what we expect, we adjust or stop

Theoretical Concerns

Potential considerations include:

  • No completed Phase 1 trial for native MOTS-c; formal pharmacokinetic, genotoxicity, and carcinogenicity data are absent
  • Additive glucose-lowering risk in patients on insulin, GLP-1 agonists, or other glucose-lowering agents has not been formally studied
  • No cancer safety data; MOTS-c is not used in patients with active or previously treated malignancy
  • Long-term repeated-dose safety in humans is not characterized

Contraindications

We do not use MOTS-c in:

  • Anyone competing in a WADA-regulated sport at any level (prohibited, no exceptions)
  • Patients with active or previously treated malignancy, or a family history that raises concern
  • Pregnancy, planned pregnancy, or breastfeeding
  • Patients on insulin or other glucose-lowering medications without clear clinical coordination
  • Anyone whose case has not been reviewed by a qualified clinician familiar with their full history

Regulatory Status and

Legal Considerations

Global Regulatory Status

No Approved Medical Use:
  • MOTS-c is not FDA approved for any therapeutic indication
  • It is on the FDA Category 2 restricted list
  • Licensed compounding pharmacies cannot prepare it in the United States

WADA Anti-Doping Status

Prohibited Substance Classification:
  • MOTS-c was added to the WADA Prohibited List on January 1, 2024 under S0 (Non-Approved Substances)
  • It also appears on the 2025 list as an example under S4 (Hormone and Metabolic Modulators, AMPK activator category)
  • Prohibited at all times, in and out of competition, in every WADA-regulated sport
  • If you compete at any level in a WADA-regulated sport, we will not prescribe it and you should not use it from any source

Legal Availability

Research and Clinical Use:
  • Research use of MOTS-c is legal in the United States for non-competing adults
  • It is not approved as a therapeutic, which is a different question from legality
  • Any use at Paragon is research-informed and under direct physician supervision
  • Source, quality, and chain of custody are discussed during your consultation

Administration and Dosing

Considerations

How It Is Administered:

  • MOTS-c is administered by subcutaneous injection in cycles
  • Specific dose, frequency, and cycle length are determined by your clinician based on your labs, goals, and the most relevant published research
  • We do not publish a standard dose on this page -- research protocols vary, and a number appropriate for one patient is not appropriate for another
  • With a compound that is WADA-prohibited and that has no completed Phase 1 trial for the native peptide, self-prescribing is particularly inadvisable

Clinical Considerations:

  • Your written protocol is built during consultation and includes clear instructions, a monitoring schedule, and a plan for what we measure and when
  • Most patients asking about MOTS-c have more upstream work available to them -- we will tell you that if it is true
  • We do not prescribe a peptide as a shortcut around foundational metabolic work
  • Professional oversight is required throughout the protocol period

How Soon Will I Feel a Difference:

  • Metabolic changes on labs (fasting insulin, HbA1c, glucose handling) have their own timeline depending on your baseline
  • Body composition changes, if they occur, reflect the underlying metabolic shift rather than a direct fat-loss mechanism
  • We do not promise exercise-equivalent outcomes in humans because that is not what the human evidence shows
  • We will set specific expectations based on your labs and goals before anything begins

Measurable Outcomes:

  • We track fasting insulin, HbA1c, glucose handling, body composition, relevant lipid markers, and your own subjective report
  • Metabolic health is mostly built, not prescribed -- resistance training, Zone 2 cardiovascular work, protein-prioritized nutrition, sleep, and stress management are the foundation
  • A peptide is a lever, not a substitute; your plan reflects that because that is what works
  • Longer telomeres on a commercial test is not the same thing as a longer healthspan, and the same honest framing applies here

Conclusion

See whether MOTS‑c fits your plan.

At Paragon, every plan begins with a process designed to cut through the noise and focus on what truly matters for your health. We start with a full intake, a careful review of your current labs, and an honest conversation about your goals—both the outcomes you hope to achieve and the evidence that will guide us there. From that foundation, we evaluate the tools available. MOTS‑c is one option, but it is never assumed. If it proves to be the right fit for your physiology and aligns with the changes most likely to move the needle for you, we will recommend it with clarity. More often, however, there is foundational work to be done first—steps that create the conditions for real progress—and we will tell you exactly what that looks like.

Our role is not to chase the latest compound, but to help you build a plan that is grounded in evidence, tailored to your biology, and focused on sustainable change. Every recommendation is made with transparency, precision, and a commitment to guiding you toward the interventions that matter most for your long‑term health and resilience.

Book a consultation
Book a consultation

MOTS-c SCIENTIFIC

DATA SUMMARY

Parameter
Value
Full Name
Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c)
Peptide Structure
16-amino acid peptide: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR)
Molecular Formula
C₁₀₁H₁₅₂N₂₈O₂₂S₂
Molecular Weight
2,174.6 Da
CAS Number
1627580-64-6
PubChem CID
146675088
Genomic Origin
Encoded by a 51-base-pair short open reading frame (sORF) within the mitochondrial 12S rRNA gene (MT-RNR1); translated in the cytoplasm using the standard genetic code (not the mitochondrial code); polyadenylated transcript exported from mitochondria prior to translation
Discovery
First identified in 2015 by Lee et al. (Cell Metabolism, PMID 25738459) via in silico sORF screening of human 12S rRNA; first mitochondrial peptide known to translocate to the nucleus
Sequence Conservation
First 11 residues (MRWQEMGYIFY) highly conserved across 14 species including humans and mice; positive selection confirmed by dN/dS ratio analysis
Endogenous Expression
Co-localizes to mitochondria in numerous tissues (brain, heart, liver, skeletal muscle, testes, kidney, spleen, intestine); circulates in plasma of both rodents and humans; levels decline with age — circulating MOTS-c is ~11% higher in young vs. middle-aged adults and ~21% higher vs. older adults (70–81 years)
Exercise Response
Endogenous skeletal muscle MOTS-c increases ~11.9-fold following exercise vs. pre-exercise; persists 4h post-exercise in muscle. Circulating levels increase 1.6-fold during exercise and 1.5-fold after exercise, returning to baseline within 4 hours
Chemical Stability
Reconstituted in water: stable with no significant degradation for ≥30 days at 4°C (confirmed by high-resolution MS tracking methionine oxidation). Lyophilized powder: stable long-term at −20°C. Contains two methionine residues susceptible to oxidation — primary degradation marker
Half-Life
Biological half-life in humans not formally established. Estimated 1–2 hours based on exercise-induced circulating level kinetics (return to baseline within 4h). In vivo exogenous half-life likely short; duration of biological activity exceeds circulating half-life due to intracellular and nuclear mechanisms
Bioavailability
Subcutaneous injection primary route in preclinical research. Oral and intraperitoneal routes used in animal studies. Oral bioavailability in humans not established. Low oral bioavailability, poor stability, and short half-life identified as key clinical development challenges. Cell-penetrating analogue (CB4211) developed to improve delivery
Pathway
Effect
AMPK Activation (Primary)
Inhibits the folate cycle at the level of 5-methyltetrahydrofolate (5Me-THF), disrupting the tethered de novo purine biosynthesis pathway; this causes accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a potent endogenous AMPK activator. AICAR → AMPK activation → improved glucose uptake and fatty acid oxidation in skeletal muscle. This mechanism distinguishes MOTS-c from metformin (which acts primarily on liver) and targets skeletal muscle as primary site of action
Nuclear Translocation
Under metabolic stress, MOTS-c translocates from mitochondria to nucleus in an AMPK-dependent manner; requires hydrophobic interactions (possibly involving chaperone proteins); binds to ARE (Antioxidant Response Element)-regulated transcription factors to regulate nuclear gene expression including GLUT4, STAT3, IL-10, PGC-1α, and NRF2-regulated genes; improves cellular stress resistance
Insulin Sensitivity / GLUT4
AMPK activation upregulates GLUT4 (glucose transporter type 4) expression and membrane translocation in skeletal muscle; activates the Akt pathway in muscle cells; improves insulin-stimulated glucose disposal (70–85% of postprandial glucose disposal occurs in skeletal muscle); reverses age-related and HFD-induced insulin resistance
Anti-Inflammatory Signaling
AMPK activation inhibits MAP kinase (ERK, JNK, P38) and c-Fos expression; reduces pro-inflammatory cytokines; increases anti-inflammatory cytokines (e.g., IL-10); inhibits NF-κB activation; reduces NLRP3 inflammasome activation (via ROS/TXNIP/NLRP3 pathway modulation in cardiac tissue)
Mitochondrial Protection / NRF2
MOTS-c/NRF2 interaction upregulates mitochondrial protective gene expression; restores mitochondrial respiration and ATP content in senescent and diabetic cells; promotes mitochondrial biogenesis (via PGC-1α, tFAM); reduces reactive oxygen species; activates SIRT1 downstream of AMPK
Cardiovascular Protection
Activates AMPK pathway in cardiomyocytes; activates NRG1-ErbB4 and NRG1/ErbB4/CEBPβ pathways to restore cardiac function; inhibits CCN1/ERK1/2/EGR1 pathway to repair myocardial damage; reduces oxidative stress and apoptosis in cardiac cells; mitofusion required for MOTS-c-induced GLUT4 translocation in cardiomyocytes
Bone / Immune Effects
Inhibits osteolysis by modulating osteocyte-osteoclast crosstalk and suppressing local inflammation (Yan et al., Pharmacol Res 2019); prevents pancreatic islet destruction in autoimmune diabetes by preserving β-cell function (Kong et al., Cell Rep 2021); anti-MRSA activity demonstrated in murine infection model (Zhai et al., Mol Immunol 2017)
Genetic Association / Longevity
MOTS-c gene polymorphisms (particularly K14Q variant in mtDNA) associated with human longevity in population studies (Fuku et al., Aging Cell 2015); K14Q polymorphism also associated with muscle fiber composition and muscular performance; constitutes a pro-diabetogenic mtDNA variant in some populations (Zempo et al., 2021)
Application
Model
Dose / Route
Outcome
Insulin Resistance / HFD Obesity
CD-1 mice on high-fat diet (Lee et al. 2015, Cell Metab, PMID 25738459)
Various doses SC; 15 mg/kg used in key studies
Prevented HFD-induced obesity and hyperinsulinemia; improved glucose tolerance; restored insulin sensitivity to levels comparable with normal-diet controls; no effect on body weight in normal-diet mice; GLUT4 upregulation confirmed as mechanism
Age-Related Insulin Resistance
Aged male mice (Lee et al. 2015; Guo et al. 2020)
Various doses SC × 7 days
Insulin sensitivity of old mice restored to levels equivalent to young mice after 7 days of MOTS-c intervention; increased glucose uptake in soleus muscles; reversed age-dependent reduction in MOTS-c levels in skeletal muscle and blood
Age-Related Physical Decline
Aged mice (Reynolds et al. 2021, Nat Commun 12:470, PMID 33473109)
15 mg/kg SC
Systemic MOTS-c administration reversed age-dependent physical decline; improved grip strength, treadmill endurance, and muscle homeostasis; regulated transcriptional programs linked to muscle aging; MOTS-c described as exercise-induced regulator of age-dependent decline
Cardiovascular / Heart Failure
Pressure-overload heart failure model (mice); diabetic rat cardiac models (Zhong et al. 2022; Li et al. 2022; Yuan et al. 2021)
0.5–5 mg/kg SC or IP
Prevented heart failure development under pressure overload via AMPK activation; restored cardiac function in diabetic rats via NRG1-ErbB signaling; improved myocardial performance during exercise training; reduced left ventricular wall thickening; repaired myocardial damage via CCN1/ERK1/2/EGR1 inhibition
Type 1 and Gestational Diabetes
STZ-induced T1D mice and rats; gestational diabetic mice (Yin et al. 2022; Kong et al. 2021)
10 mg/kg IP or SC
Reduced hyperglycemia; improved insulin resistance in gestational diabetes mellitus; prevented pancreatic islet destruction in autoimmune (NOD mouse) T1D; restored blood glucose levels in STZ-diabetic animals; preserved β-cell mass
Inflammation / Analgesia
Murine formalin test (Yin et al. 2020, Eur J Pharmacol 870:172909)
Intraperitoneal injection, dose-dependent
Dose-dependent reduction in licking time (phase 2 of formalin test); significant decrease in pro-inflammatory cytokines; increase in anti-inflammatory cytokines; effect blocked by AMPK antagonist Compound C, confirming AMPK-dependence; inhibited ERK, JNK, P38, and c-Fos activation
Postmenopausal Metabolic Dysfunction
Ovariectomized mice (Lu et al. 2019, J Mol Med)
Various doses SC
Partially reversed ovariectomy-induced obesity and insulin resistance; increased adipose thermogenic activation; regulated adipose homeostasis; MOTS-c levels decline with estrogen withdrawal, consistent with hormone-peptide crosstalk
T2D Cardiac Mitochondrial Function
Streptozotocin + high-fat diet T2D rats (2025, PMC12257629)
0.5 mg/kg SC × 8–12 weeks
Restored mitochondrial respiration per tissue mass; improved citrate synthase activity; decreased fasted blood glucose; reduced left ventricular wall thickness 8%; increased mitochondrial biogenesis markers (PGC-1α, tFAM); improved AMPK signaling and GLUT4 expression in skeletal muscle
MOTS-c Analogue (CB4211) — NAFLD
Diet-induced obesity mouse model; STAM™ NAFLD mouse model (CohBar, preclinical)
5 or 15 mg/kg IP BID × 21 days
Reduced body weight and liver steatosis; greater fat-loss specificity than liraglutide; NAFLD Activity Score reduced 33% (15 mg/kg); reduced liver triglycerides and plasma ALT; led to Phase 1a/1b human trial (NCT03998514)
Study Type
Population
Results
Limitations
CB4211 Phase 1a/1b Trial (NCT03998514)
20 obese adults with ≥10% liver fat; 11 treated (25 mg CB4211 SC once daily), 9 placebo × 28 days (CohBar Inc., 2021)
Met primary safety endpoint; CB4211 is a MOTS-c analogue, not native MOTS-c itself; topline results released 2021; CohBar subsequently discontinued operations — full data not published in peer-reviewed journal
Small sample size (n=20); only 28-day duration; CB4211 ≠ native MOTS-c; no published peer-reviewed efficacy data; company discontinued; no Phase 2 follow-up
Observational / Cross-Sectional: Plasma MOTS-c vs. Metabolic Markers
Multiple human cohort studies including obese Chinese male children/adolescents (5–14 years, n=various); adult men (31–38 years); older adults (70–81 years)
Obese boys/adolescents had significantly lower circulating MOTS-c (−20.3%); plasma MOTS-c in men negatively correlated with fasting insulin, HbA1c, and BMI; 70–81-year-olds had ~21% lower MOTS-c vs. 18–30-year-olds; no correlation with BMI found in 31–38-year-old cohort (contradictory result)
Observational only — no intervention; contradictory BMI findings between age cohorts; small sample sizes; correlational data cannot establish causality; confounded by individual variation
Exercise Studies (Human)
Healthy adults (Reynolds et al. 2021, Nat Commun; Hyatt 2022, Physiol Rep)
Exercise increases skeletal muscle MOTS-c 11.9-fold vs. pre-exercise; persists 4h post-exercise. Circulating MOTS-c +1.6-fold during, +1.5-fold after exercise; returns to baseline within 4h. Long-term exercise training increases skeletal muscle MOTS-c and improves acute exercise performance after single exogenous dose. Single dose improved performance in trained subjects (Hyatt 2022)
Small sample sizes; not a therapeutic trial; performance effects of exogenous dosing based on limited data; confounded by exercise protocol variation
Overall Clinical Evidence Level
N/A
No completed, peer-reviewed Phase 2 or Phase 3 therapeutic trials for native MOTS-c in any indication. Closest human trial used a modified analogue (CB4211) and was not fully published. Endogenous MOTS-c levels are robustly correlated with metabolic health in observational studies. Preclinical therapeutic evidence is extensive but not translated to human trials.
No FDA-approved or investigational new drug (IND) application known for native MOTS-c. Major translational barriers: short half-life, low oral bioavailability, poor stability, difficulty penetrating cells without degradation, and absence of a well-defined receptor. Comprehensive clinical development has not begun.
Parameter
Finding
Acute Tolerability
No acute toxicity observed in preclinical studies across multiple species and routes; CB4211 analogue met primary safety endpoint in Phase 1a/1b human trial (n=20, 28 days)
Endogenous Context
MOTS-c is a naturally occurring mitochondrial-derived peptide present in all humans and rodents from birth; endogenous levels positively correlate with metabolic health markers, providing some baseline safety context for physiological concentrations
Metabolic Safety
No evidence of hypoglycemia in animal models even at high doses; does not impair glucose tolerance; does not affect body weight in normal-diet animals; no hepatotoxicity (unlike metformin, AICAR, or methotrexate — which all activate AMPK but have liver toxicity profiles)
Sex Effects
MOTS-c shows a documented sex effect — levels more heavily impacted by metabolic status in males than females in some studies; ovariectomy (estrogen withdrawal) reduces MOTS-c and worsens metabolic function; sex-specific dosing effects not fully characterized
Immunogenicity
No immunogenicity events published in preclinical literature; as an endogenous human peptide, immunogenic risk is theoretically lower than for foreign proteins; however, no formal immunogenicity testing per ICH standards has been conducted for exogenous administration
Potential Maladaptive Risk
In longevity model organisms, excessive mitochondrial stress buffering may reduce the beneficial mitohormetic response (cellular "toughening" via mild stress); it has not been established whether excess MOTS-c supplementation could become maladaptive — a theoretical concern without established evidence in mammals
Long-term Safety
No long-term human safety data; no formal toxicology studies (genotoxicity, carcinogenicity, reproductive toxicity) per ICH guidelines conducted for native MOTS-c; chronic effects unknown; no dose-escalation Phase 1 safety trial completed for native peptide
Drug Interactions
No published drug interaction studies; primary mechanism (AMPK activation) overlaps with metformin — combined use may theoretically produce additive effects; pharmacodynamic interactions with other AMPK modulators, insulin sensitizers, or exercise-inducing protocols not formally studied
Route
Application
Notes
Subcutaneous Injection
Insulin resistance, aging, exercise mimetic, cardiovascular, metabolic
Primary route in most preclinical studies; doses range 0.5–15 mg/kg depending on model and duration; longer treatment periods (8–12 weeks) use lower doses (0.5–5 mg/kg); shorter periods (2–4 weeks) use higher doses (10–15 mg/kg)
Intraperitoneal Injection
Inflammation / analgesia; NAFLD (CB4211)
Used in formalin pain/inflammation model; CB4211 analogue used IP BID in NAFLD mouse model; common route in acute rodent pharmacology studies
Oral Administration
IBD-related inflammation (MOTS-c analogue, investigational)
An orally administered MOTS-c analogue ameliorated DSS-induced colitis in mice by inhibiting inflammation and apoptosis (Jiang et al., Eur J Pharmacol 2023). Native MOTS-c oral bioavailability in humans not established; poor stability in GI tract is a key limitation for native peptide
Cell-Penetrating Analogues
NAFLD, metabolic disease (CB4211, CohBar)
CB4211 is a modified MOTS-c analogue with enhanced cell penetration; 25 mg SC once daily used in Phase 1a/1b trial; CohBar discontinued operations post-trial — development status uncertain
Synthetic Biology / Engineered Bacteria
Investigational delivery platform
Proposed approach: introducing MOTS-c gene into probiotic bacteria (e.g., Lactobacillus, E. coli Nissle1917) for precise, controllable gut expression; remains preclinical concept only; challenges include bacterial virulence, uncontrolled immune response, and biosafety concerns
Authority
Classification
Status
FDA (USA)
Category 2 — "Significant Safety Risks" (503A Bulk Drug Substances List)
Not approved for any human therapeutic indication. Placed on FDA Category 2 list (late 2023–2024), prohibiting compounding pharmacies from preparing MOTS-c under 503A rules.
WADA
S0 — Non-Approved Substances; Prohibited at All Times
Explicitly added to the WADA Prohibited List effective January 1, 2024 (2024 List, S0 category). WADA noted MOTS-c is "heavily marketed by wellness and anti-aging clinics as a weight loss peptide" despite not being approved for human therapeutic use. Prohibited in all sports, both in- and out-of-competition. Athletes testing positive face sanctions.
EU / UK
Unapproved; research use only
Not approved by EMA or MHRA for any indication; available only as unregulated research chemical
Australia (TGA)
Unapproved substance
Not approved for therapeutic use; cannot be prescribed or sold for clinical use without specific TGA authorization
Research Use
Investigational research compound
Available as research-grade peptide from suppliers; intended for laboratory use only; pharmaceutical-grade compounding currently restricted in the US pending formal FDA reclassification. No IND application for native MOTS-c known to be active.
Pharmaceutical Development
Preclinical / No completed therapeutic trials for native peptide
No Phase 2 or Phase 3 trials for native MOTS-c in any jurisdiction. CB4211 analogue (CohBar) completed Phase 1a/1b (NCT03998514) for NAFLD but company discontinued. Key development barriers: short half-life, poor oral bioavailability, cell penetration challenges, and undefined receptor. Active academic research ongoing globally — metabolic disease, aging, and cardiovascular primary focus areas.

Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. MOTS-c is not FDA approved for any therapeutic indication and is classified as Category 2, meaning it cannot be prepared by licensed US compounding pharmacies. MOTS-c is prohibited under WADA S0 and S4 categories and must not be used by anyone competing in a WADA-regulated sport at any level. Any use at Paragon is research-informed and under direct physician supervision, for non-competitive adults only. Patients should consult with a qualified clinician and ensure regulatory compliance before considering any use of MOTS-c.